RecruitingPhase 2NCT06380907

A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis

A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical Gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis

Sponsor

Zai Lab (Hong Kong), Ltd.

Enrollment

250 participants

Start Date

May 22, 2024

Study Type

INTERVENTIONAL

Conditions

Plaque Psoriasis

Summary

A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo ZL-1102 0% w/w gel BID for 16 weeks, a drug called Placebo ZL-1102 0% w/w gel QD for 16 weeks, and others for people with plaque psoriasis. The study is currently recruiting participants at 10 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGZL-1102 1% w/w gel BID for 16 weeks

ZL-1102 1% w/w gel BID for 16 weeks

DRUGZL-1102 3% w/w gel BID for 16 weeks

ZL-1102 3% w/w gel BID for 16 weeks

DRUGZL-1102 3% w/w gel QD for 16 weeks

ZL-1102 3% w/w gel QD for 16 weeks

DRUGPlacebo ZL-1102 0% w/w gel BID for 16 weeks

Vehicle 0% w/w gel BID for 16 weeks

DRUGPlacebo ZL-1102 0% w/w gel QD for 16 weeks

Vehicle 0% w/w gel QD for 16 weeks

Locations(10)

Zai Lab Site 5013

Phillip, Australian Capital Territory, Australia

Zai Lab Site 5021

Kogarah, New South Wales, Australia

Zai Lab Site 5016

Kotara, New South Wales, Australia

Zai Lab Site 5020

Birtinya, Queensland, Australia

Zai Lab Site 5019

Coorparoo, Queensland, Australia

Zai Lab Site 5017

Woolloongabba, Queensland, Australia

Zai Lab Site 5014

Carlton, Victoria, Australia

Zai Lab Site 5015

Melbourne, Victoria, Australia

Zai Lab Site 5002

Melbourne E., Victoria, Australia

Zai Lab Site 5018

Parkville, Victoria, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06380907

Related Trials

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967383 locations

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT0477207963 locations

A Phase 3 Clinical Study of QL2106 Injection

NCT075116471 location

Modifying PEST for Psoriatic Arthritis Screening

NCT0638205129 locations

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

NCT0729056936 locations